Coloplast A/s Class B · OMXCOP:COLO_B

Coloplast A/s Class B — Investor Presentation (May 2015)

55 slides from Coloplast A/s Class B's investor presentation, May 7, 2015

  1. Slide 1: Meet the Management Event

    New production building in Nyírbátor, Hungary Meet the Management Event London, 7 May 2015

  2. Slide 2: Forward-looking statements

    Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements

  3. Slide 3: Today's programme

    Today’s programme  11:45 - Q2 results presentation  12:30 - Lunch  13:15 - Q&A break-out sessions  15:05 - Coffee and refreshments  15:45 - Q&A break-out sessions  17:35 - Drinks in the George pub at Andaz Page 3

  4. Slide 4: The Coloplast organisation as it stands today

    The Coloplast organisation as it stands today Coloplast Group Chronic Care Strategic Business Units Ostomy Care Continence Care Wound Care Skin Care Urology Care Marketing Marketing SU Porgès Global Marketing Sales Sales Marketing Marketing R&D (incl. R&D Sales Sales Consumer R&D R&D Sales Regions P

  5. Slide 5: We strengthen our commercial leadership in Chronic Care

    We strengthen our commercial leadership in Chronic Care and integrate Global R&D into Global Operations Chronic Care Kristian Villumsen Products & Consumer Payers & Commercial North Emerging Europe Asia Brands Excellence Trade Excellence America Markets Marketing Sales Global Operations Allan Rasmus

  6. Slide 6: Urology Care performance impacted by challenging Q2 for Men's Health

    Urology Care performance impacted by challenging Q2 for Men’s Health Comments Performance  H1 organic sales growth was 5% Revenues (mDKK) Reported growth (%)  Growth primarily driven by sale of Organic growth (%) Endourology products in France, Germany and Saudi Arabia 12 11 9 9 8 8 8  Titan® pen

  7. Slide 7: Wound Care delivered 12% organic growth in H1

    Wound Care delivered 12% organic growth in H1 mainly driven by Biatain® Silicone in Europe and China Comments Performance  H1 organic sales growth in WSC was 9%. Revenues (mDKK) Organic growth in Wound Care alone was 12% Reported growth (%) Organic growth (%)  Growth driven by Biatain® sales in pa

  8. Slide 8: Operating profit up by 11% in H1 2014/15

    Operating profit up by 11% in H1 2014/15 but operating margin of 33% on par with same period last year Comments Performance  EBIT grew 11% to DKK 2,213m with a margin EBIT (mDKK) * of 33% EBIT margin (%) *  Gross margin came in at 69% on par with last Gross margin (%) year 69 68 69 69 69 − Driven

  9. Slide 9: Free Cash Flow impacted mainly by sale of bonds

    Free Cash Flow impacted mainly by sale of bonds to fund dividend payments Comments Performance  Free cash flow was DKK 965m compared to FCF (mDKK) DKK 531m in H1 2013/14 FCF-to-Sales (%) 26 − EBITDA DKK 246m higher (before special 20 19 items*) 15 14 12 2,977 10.0 − NWC-to-sales of approx 26%, 2%-p

  10. Slide 10: Guidance for 2014/15

    Guidance for 2014/15 points towards further market share gains and continued margin expansion Guidance Guidance Long term 14/15 14/15 (DKK) ambition Sales growth 8-9% (organic) 13-14% 7-10% p.a. EBIT margin ~34% (fixed) ~34% +50-100 bps p.a. CAPEX (DKKm) ~650 ~4-5% of sales Tax rate ~24% - Page 10

  11. Slide 11: H1 14/15 organic growth of 7%

    H1 14/15 organic growth of 7% reflects improved performance in Q2 Highlights Performance Revenue (mDKK)  Organic revenue growth of 7% (11% in DKK) Organic growth (%)  Gross margin of 69% on par with last year 25.000 24.000 10 23.000 22.000 21.000 9 20.000 19.000 18.000 7  EBIT margin of 33%, both

  12. Slide 12: H1 14/15 organic growth was 7% against market growth of ~5%

    H1 14/15 organic growth was 7% against a market growth of ~5% H1 14/15 revenue by business area H1 14/15 revenue by geography Business Reported revenue Organic growth Geographic Reported revenue Organic growth area mDKK In percent area mDKK In percent Ostomy European 2,699 6% 4,323 5% Care markets C

  13. Slide 13: Our Ostomy Care business grew 6%

    Our Ostomy Care business grew 6% - growth continues to be driven by SenSura® range and Brava® accessories Comments Performance  H1 organic sales growth was 6% Revenues (mDKK)  Satisfactory growth in China, Southern Reported growth (%) Europe, US, Nordic markets offset by Organic growth (%) negativ

  14. Slide 14: Continence Care growth driven by SpeediCath and Peristeen

    Continence Care growth continues to be driven by SpeediCath® intermittent catheters and Peristeen® Comments Performance  H1 organic sales growth was 8% Revenues (mDKK) Reported growth (%)  Growth driven by the SpeediCath® portfolio of ready-to-use intermittent catheters and in Organic growth (%) p

  15. Slide 15: Leading intimate healthcare

    Leading intimate healthcare Introduction to Coloplast Page 15

  16. Slide 16: Coloplast has four business areas all with global sales presence

    Coloplast has four business areas all with global sales presence Group revenue FY 2013/14 by segment Group revenue FY 2013/14 by geography X = Global position Emerging markets 14% Ostomy Continence Care Care 41% 36% Other DKK developed DKK #1 12.4 bn #1 markets 12.4 bn 20% European markets Urology 6

  17. Slide 17: Coloplast specializes in intimate healthcare needs

    Coloplast specializes in intimate healthcare needs Who are our typical users How do we help them? Ostomy People who have had their intestine SenSura® Mio Care redirected to an opening in the Ostomy bag abdominal wall Continence People in need of bladder or bowel SpeediCath® management Compact male C

  18. Slide 18: Intimate health care is characterized by stable trends

    Intimate health care is characterized by stable trends Growing elderly population increases Demographics customer base for Coloplast products Expanding healthcare coverage for Emerging markets populations in emerging markets increases addressable market Earlier detection and cure, eventually reduces

  19. Slide 19: Strong market positions in Europe and potential outside Europe

    Coloplast has strong market positions in Europe and great commercial potential outside Europe Europe Developed Ostomy Continence Urology Wound Care Emerging Addressable 13 -14 billion DKK ~9 billion DKK 9 -10 billion DKK ~14 billion DKK market 4 - 5% growth 4 - 6% growth 3 - 5% growth 2 - 4% growth

  20. Slide 20: Our strategy remains centred on value creation through profitable organic growth

    Our strategy remains centred on value creation through profitable organic growth How we compete… …Where we compete 1 Develop and market the world’s best 5 Untapped potential in Europe products 6 Increased momentum in Other 2 Interact and build consumers relations Developed Markets – incl. breakthrou

  21. Slide 21: Key Value Driver #1: Many global growth opportunities

    Key Value Driver #1: Many global growth opportunities with significant longer term potential Untapped pockets of growth in Europe e.g. in • UK • Germany Increase • Italy market share in • USA • Canada • Japan Build on and • Australia accelerate growth platform e.g. in • China • Brazil • Argentina De

  22. Slide 22: Key Value Driver #2: Invest in Consumer Care activities

    Key Value Driver #2: We continue to invest in Consumer Care activities to increase our interactions with the users of our products Hospital H General CARE practitioner Coloplast Distributors Pharmacies Consumer Bandagists Home Health Care DtC Page 22

  23. Slide 23: Key Value Driver #3: Efficiency improvements in production

    23 Key Value Driver #3: We see more potential for efficiency improvements in our production Production by country* 5% 10% Thisted Hungary Minneapolis Mørdrup China Mankato Denmark 25% 60% US/ France Nyirbátor Sarlat Tatabánya *Average usage of raw material (RM) and semi finished goods (SFG) COGS by

  24. Slide 24: Key Value Driver #4: Economies of scale in cost functions

    Key Value Driver #4: And we believe we can continue to drive economies of scale in our cost functions Cost item Development Outlook Outlook As reported Percentage of revenue Scalability potential Investments requirements COGS 50 38,7 31,3 High Medium 0 09/10 13/14 Distribution 29,5 28,3 Medium High

  25. Slide 25: Organic value creation provides high cash returns and share buy-backs

    Focus on organic value creation provides for high cash returns and continued share buy-backs Comments Performance  DKK 1bn share buy-back initiated in March Share buy-back (mDKK) 2014 Dividends (mDKK)  Second half of buy-back program Total payouts/FCF (%) commenced in Q2 14/15 and will be 119 comp

  26. Slide 26: Coloplast can continue to deliver stable shareholder returns

    Therefore we believe Coloplast can continue to deliver stable shareholder returns through.. Organic growth  Stable market trends in our Chronic Care EBIT Margin * 33% business 16% 10%  Strong retention program and innovative D-t-C activities 10% 9% 7%  Increased focus on growing the business 03/0

  27. Slide 27: Appendices

    Appendices Page 27

  28. Slide 28: The Coloplast share (COLO'B-KO)

    The Coloplast share (COLO’B-KO) Share Capital Ownership Coloplast share listed on NASDAQ Copenhagen since 1983 2% 9% ~ 123 billion DKK (~ 18 billion USD) market 4% cap @ ~560 DKK per share (incl. A shares) 45% Two share classes: 33%  18m A shares carry 10 votes (family) 7%  202m B shares carry 1 v

  29. Slide 29: Capital structure

    Capital structure Comments Performance NIBD (mDKK)  No interest bearing debt – will only be raised in connection with a major acquisition NIBD/EBITDA *  Excess liquidity is returned to shareholders in 1,2x a combination of dividend and share buy- backs 0,6x 2.297 0,2x  Share buy-backs of DKK 500m

  30. Slide 30: Key Value Ratios

    Key Value Ratios Profitability drivers Free Cash Flow drivers 45.0 42.1 40.0 36.8 38.7 35.8 36.3 34.1 35.4 35.0 33.4 30.6 32.4 31.3 31.5 30.4 30.0 27.1 29.5 29.4 28.8 25.7 28.5 28.8 23.7 23.1 22.2 22.5 23.9 28.3 23.1 25.0 22.0 20.0 6.5 7.0 15.0 4.8 5.8 5.9 4.3 5.6 3.8 4.4 4.6 10.0 3.2 3.1 4.3 4.1 4.

  31. Slide 31: Coloplast revenue development by business area

    Coloplast revenue development by business area Ostomy Care Continence Care 12000 9 1012,000 13 8 8 8 8 11 10000 7 10,000 10 7 6 5 6 9 5 6 8000 4 8,000 8 8 8 2 7 6000 4,633 4,849 5,091 0 6,000 4,266 4,081 4,438 -2 3,456 3,831 -4 4,000 4000 2,699 2,430 2000 -6 2,000 -8 0 -10 0 3 10/11 11/12 12/13 13/1

  32. Slide 32: Coloplast revenue development by geography and total

    Coloplast revenue development by geography and total Europe Other developed 5 6 5 6 8 15 15 4 4 5 6 5 10 9 6 7 7,388 7,749 8,221 5 4 7,000 4 4 4,323 1,987 2,288 2,395 2,479 1,398 10/11 11/12 12/13 13/14 YTD 10/11 11/12 12/13 13/14 YTD Emerging Markets Coloplast total 9 6 11 7 7 7 24 8 7 20 6 14 21 1

  33. Slide 33: We aim to grow our Emerging Markets business by 25% per year

    We aim to grow our Emerging Markets business by 25% per year through focused execution in selected markets We have selected core growth markets We have a clear EM value creation strategy Core  China  Argentina 1 Expand China growth  Brazil  Greece markets  Russia  Poland 2  Expand Brazil New

  34. Slide 34: US Mesh litigation – Overview of current financial impact

    US Mesh litigation – Overview of current financial impact TBD Summary Financial Impact H1 14/15  Coloplast estimates a total of around 7,000 claims EBIT 2,213 against the company. A total DKK 1.5bn has been EBIT before special items 2,213 provisioned and this is currently considered sufficient EBIT

  35. Slide 35: Mesh litigation status & events leading up to 1 bDKK provision

    Mesh litigation status & events leading up to 1 bDKK provision Nov. 13, 2014: July 23, 2012: June 2013: Aug. 15, 2013: April 3, 2014: May 2, 2014: Sept. 5, 2014: Verdict vs BSC Verdict vs Bard Verdict for Verdict vs Bard Verdict vs Ethicon Coloplast provision Verdict vs Ethicon BSC MDL (FL): CA Stat

  36. Slide 36: Healthcare reform landscape

    Healthcare reform landscape Intensifying reform pressure France Still awaiting periodic review of OC and CC. Price cut Stable reform environment in WC implemented Oct` 2014. Germany Reimbursement level for CC under pressure. Holland Reimbursement level for OC and CC under pressure. Italy Tracking po

  37. Slide 37: Coloplast Care is a retention program

    Coloplast Care is a retention program bringing us closer to our consumers Objective Through Coloplast Care we… Key benefits C Connect to consumers and form lifetime bond An online support programme Enrollment through all relevant consumer touch points NPD gain and retention of new users when A Advis

  38. Slide 38: Direct-to-Consumer activities is a new marketing channel

    Direct-to-Consumer activities is a new marketing channel Objective Objective DtC is direct, individualized marketing… Examples of DtC investments New website Expertise Market to the individual’s need Conversion, Customized message up-selling and Specific products cross-selling to and dialogue and se

  39. Slide 39: Introducing Ostomy Care

    Introducing Ostomy Care Key products • Colorectal cancer (est. 45%) Disease areas • Bladder cancer (est. 10%) • Diverticulitis (est. 15%) • Inflammatory bowel disease (est. 10%) • Other (est. 20%) Customer • Nurses, mainly stoma care nurses groups • People with a stoma • Wholesalers/distribution • H

  40. Slide 40: Introducing Ostomy Care Accessories

    Introducing Ostomy Care Accessories Brava® is a range of ostomy accessories designed to reduce leakage Market or care for skin, to make our end-users feel secure. Brava® was fundamentals • Market size of DKK 2bn launched in April 2012 and the range includes 10 different products. • Market growth of

  41. Slide 41: Introducing Continence Care

    Introducing Continence Care Key products Disease • Spinal Cord Injured, SCI areas • Spina Bifida, SB • Multiple Sclerosis, MS • Benign prostatic hyperplasia, BPH & prostatectomy patients • Elderly Customer groups • Continence or home care nurses • Wholesalers/distributors • Hospital purchasers and G

  42. Slide 42: Introducing Bowel Management

    Introducing Bowel Management Disease areas Faecal incontinence (management Key products products only) Customer Customer groups groups & • Spinal Cord Injured, SCI call points • Spina Bifida, SB • Multiple Sclerosis, MS Call points • Rehab centers • Pediatric clinics Peristeen® Anal Irrigation Anal

  43. Slide 43: Introducing Urology Care

    Introducing Urology Care Treatment (surgical) of urological disorders Key products (implants and surgical disposables) Disease areas • Urinary incontinence • Pelvic organ prolapse • Erectile dysfunction • Enlarged prostate • Kidney and urinary stones Customer • Surgeons groups • Purchasing departmen

  44. Slide 44: Introducing Wound Care

    Introducing Wound Care Key products Disease areas Chronic wounds • Leg ulcers • Diabetic foot ulcers • Pressure ulcers Customer Hospitals Groups & • Wound care committees call points • Specialist nurses/doctors • (Purchasers) Biatain® Silicone Biatain® Ag • foam dressing with • Antimicrobial foam dr

  45. Slide 45: Introducing Skin Care

    Introducing Skin Care Key products Disease areas • Moisture associated skin damage • Incontinence • Skin folds & obesity • Prevention of skin impairments Customer Hospitals groups & • Clinical Specialists call points • Supply Chain • Value Analysis Committee Sween® EasiCleanse Bath® Community • Broa

  46. Slide 46: Product market for US Skin Care

    Product market for US Skin Care • US market size estimated at USD ~1bn with ~ 5% growth • Market share: 5-10% • Main competitors include • Medline Industries • Sage Products • ConvaTec Market drivers Market limiters Market trends  Aging and obese population  Consolidation of Providers  Increase s

  47. Slide 47: Coloplast Executive Management

    Coloplast Executive Management Lars Rasmussen President, CEO • Born 1959 • With Coloplast since 1988 Anders L.-Skovgaard Allan Rasmussen Kristian Villumsen EVP, CFO EVP, Global Operations EVP Chronic Care • Born 1972 • Born 1967 • Born 1971 • With Coloplast since 2006 • With Coloplast since 1992 • W

  48. Slide 48: Corporate responsibility – external recognitions

    Corporate responsibility – external recognitions Page 48

  49. Slide 49: Income statement

    Income statement DKKm H1 2014/15 H1 2013/14 Change Revenue 6,748 6,080 11% Gross Profit 4,624 4,162 11% Gross margin 69% 68% SG&A costs -2,213 -1,986 -11% R&D costs -213 -185 -15% Other Operation Inc/exp 15 6 >100% Operating profit (EBIT) 2,213 1,997 * 11% EBIT margin 33% 33% Net financial items -93

  50. Slide 50: Balance sheet

    Balance sheet DKKm 31-Mar-15 31-Mar-14 Change Balance sheet total 10,620 9,478 12% Equity 6,473 5,847 11% Equity ratio 61% 62% Invested capital 7,365 6,194 19% ROIC before tax * 59% 59% ROIC after tax * 45% 44% Net asset value per share 29 27 7% * Before special items. After special items, ROIC befo

  51. Slide 51: Cash flow

    Cash flow DKKm H1 2014/15 H1 2013/14 Change EBITDA 2,452 1,206 >100% Change in working capital -1 -638 <-100% Net interest payments, etc. -130 60 <-100% Paid tax and other -1,097 -1,045 -5% Cash flow from operations 863 997 -13% CAPEX -325 -220 -48% Securities 403 -265 >100% Other 24 19 26% Cash flo

  52. Slide 52: Production sites

    Production sites TCC Mørdrup • Adhesives • Wound care products DK • Continence care products • Coloplast Consumer Products • Number of employees in production: ~375 TCC Thisted • Machine development • Ostomy care products DK • Number of employees in production: ~150 Sarlat • Disposable surgical urol

  53. Slide 53: Production sites

    Production sites Tatabánya • Ostomy care products • Adhesives HU • Continence care products • Number of employees in production: ~1,300 • Postponement & packaging Tata • Cross docking • Warehousing HU • Distribution & shipping • Number of employees: ~300 Nyírbátor • Catheter care products • Wound ca

  54. Slide 54: Contact Investor Relations

    Contact Investor Relations Holtedam 1 DK-3050 Humlebæk Denmark Ian Christensen Ellen Bjurgert Vice President Manager Investor Relations Investor Relations Tel. direct: +45 4911 1301 Tel. direct: +45 4911 3376 office: +45 4911 1800 office: +45 4911 1800 Fax: +45 4911 1555 Fax: +45 4911 1555 dkisec@co

  55. Slide 55: Our mission, values and vision

    Our mission Making life easier for people with intimate healthcare needs Our values Closeness… to better understand Passion… to make a difference Respect and responsibility… to guide us Our vision Setting the global standard for listening and responding Page 55

Coloplast — Investor Presentation (May 2015) on 6ix